Meals and Drug Administration in August to go over our proposed new mixture trial for pixantrone in aggressive non-Hodgkin’s lymphoma , stated James A. Bianco, M.D., CEO of the Company. On the financial entrance, we have retired all of our convertible debt due this year 2010 and taken out that obligation from our balance sheet leaving just two convertible debt maturities staying in April and December of following year for a complete of $21 million. Latest Highlights Submitted expanded and revised PIP for pixantrone within the MAA submission process. The ongoing company plans to submit an MAA for pixantrone in the next half 2010.Signed a long-term manufacturing contract with NerPharMa S.r.l for pixantrone. Submitted a proposal for a fresh scientific trial for pixantrone in aggressive NHL under the FDA’s Special Protocol Assessment procedure.Retired almost all convertible debt credited in 2010 2010 including principal and interest with a payment of $39.3 million.Reported exploratory analyses from pivotal trial provided at an advisory panel through the 15th Congress of the European Hematology Association Reported demonstrated that full responses to pixantrone are correlated with prolonged survival in sufferers with relapsed or refractory intense NHL.Related StoriesGriffith University uncovers initial 3-D picture of protein associated with cancer spreadDiscovery can offer clues to how some infections control expression of genetic materialAAO announces release of new online reference to improve eye look after childrenMohan’s lab found that withaferin A binds to both vimentin and GFAP in a exclusive pocket when these proteins are within their soluble, tetrameric type. This selecting makes withaferin A an attractive therapeutic business lead for drug-development analysis, Mohan stated, and he owes great credit to the interdisciplinary group of collaborators who contributed to extending this selecting.


Other Posts From Category "ozone therapy":

Related Posts